)
Visual
test
KalVista Pharmaceuticals
KalVista Pharmaceuticals (KALV) investor relations material
KalVista Pharmaceuticals Corporate Presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate Presentation summary9 Jan, 2026
Mission and strategy
Focus on developing therapies for rare diseases with high unmet needs, starting with hereditary angioedema (HAE).
Strategy includes leveraging global infrastructure to develop, acquire, or in-license additional innovative therapies.
EKTERLY product overview
EKTERLY is the first and only oral on-demand therapy for HAE, approved in seven major global markets.
Indicated for acute HAE attacks in patients aged 12 and older, with planned expansion to ages 2-11 in 2027.
Demonstrates rapid, sustained relief and a strong safety profile.
HAE disease and treatment landscape
HAE is a rare, lifelong disease with unpredictable, potentially life-threatening swelling attacks.
Injectable on-demand therapies are underutilized, with significant delays in treatment and many attacks going untreated.
Prior to EKTERLY, management relied on parenteral treatments and long-term prophylaxis, often with high burden and cost.
Strategy to achieve $1.5B US market for EKTERLY
Future pipeline strategy beyond EKTERLY
Significance of EKTERLY pediatric expansion
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- PSSA3
Net income up 28% and revenue up 12% in 2025, with strong growth and improved efficiency. - AB
Record AUM, strong private markets, and higher distributions despite net outflows in 2025. - GN
2026 guidance targets 3–7% organic growth and margin expansion, led by innovation and cost control. - KKR
Acquisition of Arctos creates KKR Solutions, expanding into sports, GP solutions, and secondaries. - BBVA
Record €10.5B profit, 19.3% ROTE, and major shareholder payouts highlight strong 2025. - VCTR
Record AUM, strong adjusted earnings, and expanded buybacks highlight robust Q2 2025 growth. - ROCK
2025 revenue up 1.1%, profit hit by Russia; 2026 targets growth and high investment. - VCTRQ1 2025 delivered record ETF growth, Amundi integration, and a higher $0.49 dividend.
- GENI
$1.2B acquisition creates a digital sports and gaming media powerhouse with strong growth outlook. - ABX
Record earnings, strong cash flow, and a North America gold IPO drive 2025 performance.
Next KalVista Pharmaceuticals earnings date
Q4 202613 Feb, 2026
KalVista Pharmaceuticals
Next KalVista Pharmaceuticals earnings date
Q4 202613 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
KalVista Pharmaceuticals Inc. is a biopharmaceutical company engaged in the discovery, development, and commercialization of small molecule protease inhibitors, which are primarily aimed at treating diseases with significant unmet medical needs. The company focuses on advancing a portfolio of inhibitors targeting the kallikrein-kinin system, a key pathway in the human body related to swelling and inflammation. KalVista's research has produced sebetralstat, an oral treatment for hereditary angioedema (HAE), a rare and potentially life-threatening genetic condition characterized by spontaneous episodes of swelling. Additionally, the company is exploring oral Factor XIIa inhibitors, which are in preclinical development stages, for the prophylactic treatment of HAE, along with potential therapies for thrombosis and inflammation. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage